Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer

The current view of cancer progression highlights that cancer cells must undergo through a post-translational regulation and metabolic reprogramming to progress in an unfriendly environment. In here, the importance of neddylation modification in liver cancer was investigated. We found that hepatic neddylation was specifically enriched in liver cancer patients with bad prognosis. In addition, the treatment with the neddylation inhibitor MLN4924 in Phb1-KO mice, an animal model of hepatocellular carcinoma showing elevated neddylation, reverted the malignant phenotype. Tumor cell death in vivo translating into liver tumor regression was associated with augmented phosphatidylcholine synthesis by the PEMT pathway, known as a liver-specific tumor suppressor, and restored mitochondrial function and TCA cycle flux. Otherwise, in protumoral hepatocytes, neddylation inhibition resulted in metabolic reprogramming rendering a decrease in oxidative phosphorylation and concomitant tumor cell apoptosis. Moreover, Akt and LKB1, hallmarks of proliferative metabolism, were altered in liver cancer being new targets of neddylation. Importantly, we show that neddylation-induced metabolic reprogramming and apoptosis were dependent on LKB1 and Akt stabilization. Overall, our results implicate neddylation/signaling/metabolism, partly mediated by LKB1 and Akt, in the development of liver cancer, paving the way for novel therapeutic approaches targeting neddylation in hepatocellular carcinoma.

[1]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[2]  E. Petricoin,et al.  Cancer metabolism and mass spectrometry-based proteomics. , 2015, Cancer letters.

[3]  Shelly C. Lu,et al.  Excess S‐adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis , 2013, Hepatology.

[4]  A. Paiardini,et al.  Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection. , 2013, Medical hypotheses.

[5]  D. Hardie,et al.  LKB1 and AMPK and the cancer-metabolism link - ten years after , 2013, BMC Biology.

[6]  Shelly C. Lu,et al.  Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1. , 2012, Gastroenterology.

[7]  Yi Sun,et al.  The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. , 2012, Cancer research.

[8]  Shelly C. Lu,et al.  Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation , 2012, Hepatology.

[9]  Anindya Dutta,et al.  NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.

[10]  Stephanie Roessler,et al.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. , 2010, Cancer research.

[11]  Shelly C. Lu,et al.  Liver‐specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice , 2010, Hepatology.

[12]  Shelly C. Lu,et al.  Activation of LKB1‐Akt pathway independent of phosphoinositide 3‐kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis , 2010, Hepatology.

[13]  Francis J Giles,et al.  Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. , 2010, Blood.

[14]  Geng-Hung Liu,et al.  Regulation of nucleolar signalling to p53 through NEDDylation of L11 , 2009, EMBO reports.

[15]  Frans M van der Kloet,et al.  Analytical error reduction using single point calibration for accurate and precise metabolomic phenotyping. , 2009, Journal of proteome research.

[16]  Xin Lin,et al.  The E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation , 2009, Science.

[17]  R. Shaw,et al.  The LKB1–AMPK pathway: metabolism and growth control in tumour suppression , 2009, Nature Reviews Cancer.

[18]  W. Zou,et al.  Over‐expression of pemt2 into rat hepatoma cells contributes to the mitochondrial apoptotic pathway , 2009, IUBMB life.

[19]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[20]  N. Hay,et al.  Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. , 2009, Seminars in cancer biology.

[21]  D. Xirodimas,et al.  Novel substrates and functions for the ubiquitin-like molecule NEDD8. , 2008, Biochemical Society transactions.

[22]  Shelly C. Lu,et al.  Loss of the glycine N‐methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice , 2007, Hepatology.

[23]  H. Clevers,et al.  Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer , 2007, Oncogene.

[24]  E. Gottlieb,et al.  Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer , 2006, Oncogene.

[25]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[26]  D. Assimos,et al.  Glycolate and glyoxylate metabolism in HepG2 cells. , 2004, American journal of physiology. Cell physiology.

[27]  D. Lane,et al.  Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity , 2004, Cell.

[28]  J. Klco,et al.  pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development , 2004, Molecular and Cellular Biology.

[29]  E. Albi,et al.  Chromatin sphingomyelin changes in cell proliferation and/or apoptosis induced by ciprofibrate , 2003, Journal of cellular physiology.

[30]  M. Papotti,et al.  Expression of Phosphatidylethanolamine N-Methyltransferase in Human Hepatocellular Carcinomas , 2003, Oncology.

[31]  R. Hay,et al.  NEDP1, a Highly Conserved Cysteine Protease That deNEDDylates Cullins* , 2003, Journal of Biological Chemistry.

[32]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[33]  Y. Nishizuka Protein kinase C and lipid signaling for sustained cellular responses , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  D. Vance,et al.  Phosphatidylcholine metabolism in rat liver after partial hepatectomy. Evidence for increased activity and amount of CTP:phosphocholine cytidylyltransferase. , 1991, The Biochemical journal.

[35]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[36]  D. Wallace,et al.  Mitochondria and cancer: Warburg addressed. , 2005, Cold Spring Harbor symposia on quantitative biology.

[37]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[38]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.